Literature DB >> 3719898

Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine.

P Bore, N Lena, A M Imbert, R Favre, J P Cano, G Meyer, Y Carcassonne.   

Abstract

High-dose methotrexate (HD-MTX) infusions associated with vindesine (VDS) have been used in the treatment of head and neck cancer. In a previous study, VDS was shown to increase the apparent plasma clearance of MTX. We have studied the MTX hydroxylation process in the presence of VDS. Different routes of administration have been tested (IV pushes and 24-h or 36-h infusions). A radioimmunoassay has been developed to measure 7-OH-MTX. The defined protocols enabled us to show that VDS influences not only the pharmacokinetic behavior of methotrexate but also its hydroxylation, which is decreased in presence of VDS.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3719898     DOI： 10.1007/bf00306749

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  23 in total

Review 1.  TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS.

Authors:  J R BERTINO; G A FISCHER
Journal:  Methods Med Res       Date:  1964

2.  The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells.

Authors:  R D Warren; A P Nichols; R A Bender
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

3.  The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia.

Authors:  R F Zager; S A Frisby; V T Oliverio
Journal:  Cancer Res       Date:  1973-07       Impact factor: 12.701

4.  Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer.

Authors:  G N Hortobagyi; H Y Yap; G R Blumenschein; A U Buzdar; B C Barnes; S S Legha; C L Wiseman
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

5.  Enzymatic assay for methotrexate with a centrifugal analyzer (Cobas-Bio)

Authors:  A M Imbert; T Pignon; N Lena
Journal:  Clin Chem       Date:  1983-06       Impact factor: 8.327

6.  Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM).

Authors:  T J Ervin; R Weichselbaum; D Miller; M Meshad; M Posner; R Fabian
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct

7.  Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.

Authors:  C Benz; T Tillis; E Tattelman; E Cadman
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

8.  Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck.

Authors:  T F Plasse; T Ohnuma; S Brooks; E Saponaro; J F Holland; H Biller
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

9.  Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate-leucovorin prior to definitive radiotherapy or surgery.

Authors:  T J Ervin; J Kirkwood; R R Weichselbaum; D Miller; S W Pitman; E Frei
Journal:  Laryngoscope       Date:  1981-07       Impact factor: 3.325

10.  Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer.

Authors:  A M Gewirtz; E Cadman
Journal:  Cancer       Date:  1981-06-01       Impact factor: 6.860
View more
  1 in total

Review 1.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.